Positive results were announced from the ECZTEND extension study of Adbry in atopic dermatitis who took part in a previous parent trial.

The Phase III ECZTEND study reported that patients treated with Adbry demonstrated long term safety and efficacy for up to ...

LEO Pharma has announced long term safety and efficacy data for its atopic dermatitis treatment, Adbry (tralokinumab-ldrm), demonstrating the drug’s ability to drive clear or almost clear skin ...

Positive results were announced from the ECZTEND extension study evaluating Adbry ® (tralokinumab ... and older with moderate- to- severe atopic dermatitis (AD) who took part in a previous ...

1 Tralokinumab-ldrm is marketed in the U.S. as Adbry for patients 12 years of ... to meet the unique needs of patients living with atopic dermatitis and chronic hand eczema," says Shannon ...

and Adbry ® (tralokinumab-ldrm) in the treatment of patients 12 years of age or older with moderate to severe atopic dermatitis (AD). The findings are being presented across 18 posters at the ...